Simvastatin enhances induction of inducible nitric oxide synthase in 3T3-L1 adipocytes

References

• Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–142
   PubMed Web of Science ®Google Scholar
• Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78: 915–918
   PubMed Web of Science ®Google Scholar
• Huie RE, Padmaja S. The reaction of no with superoxide. Free Radic Res Commun 1993; 18: 195–199
   PubMed Web of Science ®Google Scholar
• Pahan K, Sheikh FG, Namboodiri AM, Singh I. N-acetylcysteine inhibits induction of no production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. Free Radic Biol Med 1998; 24: 39–48
   PubMed Web of Science ®Google Scholar
• Dobashi K, Asayama K, Shirahata A. Differential effects of cyclic AMP on induction of nitric oxide synthase in 3T3-L1 cells and brown adipocytes. Free Radic Biol Med 2003; 35: 94–101
   PubMedGoogle Scholar
• Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1071
   PubMed Web of Science ®Google Scholar
• Araki S, Dobashi K, Kubo K, Yamamoto Y, Asayama K, Shirahata A. N-acetylcysteine attenuates TNF-alpha induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. Life Sci 2006; 79: 2405–2412
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Hirai A, Saito Y. Cell-anchorage, cell cytoskeleton, and Rho-GTPase family in regulation of cell cycle progression. Prog Cell Cycle Res 2000;4:19–25. Review.
   PubMedGoogle Scholar
• O'Driscoll G, Green D, Roger R. Taylor simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–1131
   PubMed Web of Science ®Google Scholar
• Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–283
   PubMed Web of Science ®Google Scholar
• Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758–1764
   PubMed Web of Science ®Google Scholar
• Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100: 2671–2679
   PubMed Web of Science ®Google Scholar
• Huang KC, Chen CW, Chen JC, Lin WW. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci 2003; 10: 396–405
   PubMed Web of Science ®Google Scholar
• Madonna R, Di Napoli P, Massaro M, Grilli A, Felaco M, De Caterina A, Tang D, De Caterina R, Geng YJ. Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 2005; 280: 13503–13511
   PubMed Web of Science ®Google Scholar
• Lin R, Liu J, Peng N, Yang G, Gan W, Wang W. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 2005; 28: 1630–1634
   PubMedGoogle Scholar
• Hattori Y, Nakanishi N, Kasai K. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc Res 2002; 54: 649–658
   PubMed Web of Science ®Google Scholar
• Kato T, Hashikabe H, Iwata C, Akimoto K, Hattori Y. Statin blocks Rho/Rho-kinase signalling disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 2004; 1689: 267–272
   PubMedGoogle Scholar
• Rattan R, Giri S, Singh AK, Singh I. Rho A negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKalpha. Free Radic Biol Med 2003; 35: 1037–1050
   PubMedGoogle Scholar
• Dobashi K, Asayama K, Nakane T, Kodera K, Hayashibe H, Nakazawa S. Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. Life Sci 2000; 67: 2093–2101
   PubMed Web of Science ®Google Scholar
• Kapur S, Picard F, Perreault M, Deshaies Y, Marette A. Nitric oxide: a new player in the modulation of energy metabolism. Int J Obes Relat Metab Disord 2000;24:S36–S40. Review.
   Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, Laharrague P, Casteilla L, Penicaud L. A role for preadipocytes as macrophage-like cells. FASEB J 1999; 13: 305–312
   PubMed Web of Science ®Google Scholar
• Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K. Analysis of an expression profile of genes in the human adipose tissue. Gene 1997; 190: 227–235
   PubMed Web of Science ®Google Scholar
• Pandey M, Loskutoff DJ, Samad F. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005; 19: 1317–1339
   PubMed Web of Science ®Google Scholar
• Goto D, Fujii S, Kaneko T, Furumoto T, Sugawara T, Tarikuz Zaman AK, Imagawa S, Dong J, Nakai Y, Mishima T, Sobel BE, Kitabatake A. Intracellular signal transduction modulating expression of plasminogen activator inhibitor-1 in adipocytes. Biochem Pharmacol 2003; 65: 1907–1914
   PubMedGoogle Scholar
• McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B–32B
   PubMed Web of Science ®Google Scholar
• van Vliet AK, van Thiel GC, Huisman RH, Moshage H, Yap SH, Cohen LH. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta 1995; 1254: 105–111
   PubMed Web of Science ®Google Scholar
• Kubota T, Fujisaki K, Itoh Y, Yano T, Sendo T, Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem Pharmacol 2004; 67: 2175–2186
   PubMed Web of Science ®Google Scholar
• Bruni F, Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Leo A, Auteri A. Different effect induced by treatment with several statins on monocyte tissue factor expression in hypercholesterolemic subjects. Clin Exp Med 2003; 3: 45–53
   PubMedGoogle Scholar
• Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, Lee YH, Kaibuchi K, Kahn BB, Masuzaki H, Kim JK, Lee SW, Kim YB. Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab 2005; 2: 119–129
   PubMedGoogle Scholar
• Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13: 95–100
   PubMed Web of Science ®Google Scholar
• Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–1892
   PubMed Web of Science ®Google Scholar
• Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 357–361
   PubMed Web of Science ®Google Scholar
• Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26: 1681–1684
   PubMed Web of Science ®Google Scholar
• Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, Ichihara K. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 2005; 28: 2092–2095
   PubMed Web of Science ®Google Scholar
• Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28: 1151–1157
   PubMed Web of Science ®Google Scholar
• Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000; 150: 121–127
   PubMed Web of Science ®Google Scholar